This work has the objective a survey of the species of plants and their uses as medicinal, which are utilized for therapeutic purposes in Northeast region of Brazil. The area of study is recognized by a rich diversity of species of plants and habitats that ranges from Rainforest, Atlantic Forest, coastal dunes systems and mangroves, to dry forests and savannas. As results, a total of 650 species belonging to 407 genera and 111 families were recorded and also their ethnomedicinal information. The floristic diversity is dominated by higher plants and only five species belonging to the families Aspleniaceae, Cyatheaceae, Equisetaceae, Polypodiaceae and Selaginellaceae were reported belonging to the Ferns group, which correspond to less than 1 % of the total of the registered species. This study aims at emphasizing the greatest importance of investigation of those species that have not been subject of pharmacological study, although their popular uses have already been reported.

/pdf/survey-of-medicinal-plants-used-in-the-region-northeast-of-2aqzfmgexu.pdf

Survey of medicinal plants used in the region Northeast of Brazil

https://febs.onlinelibrary.wiley.com/doi/pdf/10.1016/j.febslet.2005.12.009

ABC transporters involved in the transport of plant secondary metabolites.

Antileishmanial and antifungal activity of plants used in traditional medicine in Brazil

Recent advances in leishmaniasis treatment.

Leishmaniasis is a parasitic disease that presents four main clinical syndromes: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar (VL), and post kala azar dermal leishmaniasis (PKDL). Causative Leishmania are protozoan parasites that are transmitted among mammalian hosts by phlebotomine sandflies. In mammalian hosts, parasite cells proliferate inside the host phagocytic cells as round amastigotes. Infection of sandflies with Leishmania occurs during insect feeding on infected mammalian hosts. After introduction into the insect gut together with the blood meal, Leishmania amastigotes transform into elongated flagellated promastigotes that propagate in the insect gut. A new round of infection is initiated after the infected sandfly takes a blood meal from a naive mammalian host and introduces Leishmania parasites into the bite wound in the host dermis (Scheme 1). More than 20 different Leishmania species have been found to cause human leishmaniasis (Table 1).

Leishmaniasis is endemic in 98 countries and is closely associated with poverty. More than a million new cases are reported per year and 350 million people are at risk of contracting the infection. For the most severe form of leishmaniasis, VL, ∼300 000 new cases are estimated to occur annually resulting in ∼40 000 deaths. Approximately 90% of all VL cases occur in 3 endemic foci: 1. India, Bangladesh, and Nepal; 2. East Africa; and 3. Brazil. In spite of the high prevalence, currently available treatments for leishmaniasis are inadequate. Pentavalent antimonials, the standard treatment for leishmaniasis for many decades, are not efficacious in Bihar (∼60% of VL cases worldwide) any longer due to widespread resistance to the drug in this region. Several new VL treatments have emerged during the past 10–15 years, but each has serious shortcomings (summarized in Table 2). These include paromomycin (injectable, long treatment, region-dependent efficacy), miltefosine (cost, teratogenicity, long treatment), and liposomal amphotericin B (cost, hospitalization, region-dependent efficacy). An additional challenge is represented by patients with HIV/VL coinfections who are more difficult to cure (lower initial and final cure rates), have greater susceptibility to drug toxicity, and have higher rates of death and relapse.

Due to the limitations of the existing treatments, better drugs are urgently needed. Ideally, new VL drugs would be efficacious across all endemic regions, would affect cure in ≤10 days, and would cost <$10 per course (for a complete target product profile for new VL drugs, which was formulated by DNDi, see Table 4).1 Here we describe the disease history and parasite biology followed by a summary of the currently available treatments and, finally, review reports of novel small molecules with antileishmanial activity.

L.G. Rocha

Papers

A review of natural products with antileishmanial activity